Fintel experiences that on April 14, 2023,
HC Wainwright & Co.
maintained
protection of Arcadia Biosciences (NASDAQ:RKDA) with
a Purchase advice.
Analyst Worth Forecast Suggests 970.46% Upside
As of April 6, 2023,
the common one-year price target for Arcadia Biosciences is $71.40.
The forecasts vary from a low of $20.20 to a excessive of $126.00.
The common worth goal represents a rise of 970.46% from its newest reported closing worth of $6.67.
See our leaderboard of companies with the most important worth goal upside.
The projected annual income for Arcadia Biosciences
is $12MM, a rise of 20.89%.
The projected annual non-GAAP EPS
is -$0.65.
What are Different Shareholders Doing?
VitalStone Financial
holds 0K shares
representing 0.00% possession of the corporate.
Geode Capital Management
holds 177K shares
representing 20.70% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 178K shares, representing
a lower
of 0.29%.
The agency
decreased
its portfolio allocation in RKDA by 52.25% during the last quarter.
State Street
holds 102K shares
representing 11.87% possession of the corporate.
No change within the final quarter.
Harbour Investments
holds 0K shares
representing 0.00% possession of the corporate.
No change within the final quarter.
FNCMX – Fidelity Nasdaq Composite Index Fund
holds 4K shares
representing 0.43% possession of the corporate.
No change within the final quarter.
What’s the Fund Sentiment?
There are 38 funds or institutions reporting positions in Arcadia Biosciences.
That is a rise
of
3
proprietor(s) or 8.57% within the final quarter.
Common portfolio weight of all funds devoted to RKDA is 0.00%,
a lower
of fifty.36%.
Whole shares owned by establishments decreased
within the final three months by 27.89% to 2,370K shares.
The put/call ratio of RKDA is 0.00, indicating a
bullish
outlook.
Arcadia Biosciences Background Info
(This description is supplied by the corporate.)
Arcadia Biosciences is a frontrunner in science-based approaches to enhancing the standard and dietary worth of crops and meals elements. The corporate’s GoodWheat™ branded elements ship well being advantages to customers and allow client packaged items firms to distinguish their manufacturers within the market. The corporate’s GoodHemp™ seed catalog delivers genetically superior hemp seeds, transplants and extracts, making use of the corporate’s proprietary crop innovation expertise, ArcaTech™, to an rising crop.
See all Arcadia Biosciences regulatory filings.
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
